News

Deflazacort is a glucocorticoid with anti-inflammatory and immunosuppressant properties. It has fast track status, orphan drug designation and rare pediatric disease designation for DMD. One of the pivotal

Three-month follow-up data is anticipated to be available in the fourth quarter of this year. The company started the regulatory process for a phase II/III clinical trial for

"With our heritage in both rheumatology and dermatology, we are committed to providing physicians and patients a variety of biologic options, which are critical for the long-term management

The Company also reports that GTL001 drug product has completed stability assays demonstrating a five-year shelf life. As announced on January 7, 2016, Genticel evaluated Roche Molecular Systems’

The financing was led by OrbiMed Advisors, a leading investment firm focused on the healthcare sector, alongside additional investors including Frazier Healthcare Partners and Alpine BioVentures. Alpine BioVentures

In both studies, MK-1293 demonstrated non-inferiority in change from baseline A1C (a measure of average blood glucose) and similar safety to Lantus (insulin glargine) after 24 weeks. The

SHP621 (budesonide oral suspension) is in phase 3 development for the treatment of eosinophilic esophagitis (EoE). EoE is a severe, chronic and rare disease that stems from an

The facility is scheduled to be operational in September 2016, and will be FDA registered and compliant with Good Manufacturing Practice standards. Spotlight Innovation will also use the

AG-348 is wholly owned by Agios. Data will be presented today at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.